Ramipril in the treatment of vascular diseases

Bibliography

• LONN E, YUSUF S, JHA P et ell.: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. (1994) 90:2056–2069.
   Google Scholar
• SCHIEFFER B, SCHIEFFER E, HILFIKER-KLEINER D et aL: Expression of angiotensin II and interleukin 6 in human atherosclerotic plaques: potential implications for inflammation and plaque stability. Circulation (2000) 101:1372–1378.
   PubMed Web of Science ®Google Scholar
• HIGASHI Y, SASAKI S, NAKAGAWA K et al.: A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multi-center study. J. Am. Coll. CardioL (2000) 35:284–291.
   PubMed Web of Science ®Google Scholar
• SMITH W, BALL SG: Ramipril. Int. J. Clin. Pract. (2000) 54:255–260.
   PubMed Web of Science ®Google Scholar
• MORAWEITZ H, RUECKSCHLOSS U, NIEMANN B et al.: Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation (1999) 100:899–902.
   PubMed Web of Science ®Google Scholar
• GAINER JV, MORROW JD, A, KING DJ, BROWN NJ: Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N EngL J. Med. (1998) 339:1285–1292.
   PubMed Web of Science ®Google Scholar
• ERMAN A, WINKLER J, CHEN-BAL B et al.: Inhibition of angiotensin converting enzyme by ramipril in serum and tissue in man. J. Hypertens. (1991) 9:1057–1062.
   PubMed Web of Science ®Google Scholar
• MEISEL S, SHAMISS A, ROSENTHAL T: Clinical pharmacokinetics of ramipril. Clin. Pharmacokinet. (1994) 26:7–15.
   PubMed Web of Science ®Google Scholar
• VAN GRIENSVEN JM, RC, COHEN AF, LUUS HG, SEIBERT-GRAFE M, ROTHIG HJ: Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. Eur. J. Clin. PharmacoL (1995) 47:513–518.
   PubMed Web of Science ®Google Scholar
• VERHO M, LUCK C, STELTER WJ, RANGOON WALA B, BENDER N: Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. Curr. Med. Res. Opin. (1995) 13:2642–2673.
   Web of Science ®Google Scholar
• FRAMPTON JE, PETERS DH: Ramipril: An updated review of its therapeutic use in essential hypertension and heart failure. Drugs (1995) 49:440–466.
   PubMed Web of Science ®Google Scholar
• VUONG AD, ANNIS LG: Ramipril for the prevention and treatment of cardiovascular disease. Ann. Pharmacother. (2003) 37:412–419.
   PubMed Web of Science ®Google Scholar
• TODD P, BENFIELD P: Ramipril: a review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs (1990) 39:110–135.
   PubMed Web of Science ®Google Scholar
• SCHMIEDER R, MARTUS P, A: Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA (1996) 275:1507–1513.
   PubMed Web of Science ®Google Scholar
• LAFLECHE A. GAUTIER S, TOPOUCHIAN J et al.: Differential responses of the heart and vasculature to chronic blood pressure reduction in essential hypertension.. PharmacoL Ther. (1998) 64:96–105.
   Google Scholar
• NIELSEN FS, SATO A, ALI S et aL: Beneficial impact of ramipril on left ventricular hypertrophy in normotensive NIDDM patients.Diabetes Care (1998) 21:804–809.
   PubMed Web of Science ®Google Scholar
• CACCIAPUOTI F, CAPASSO A, MIRRA G et al.: Prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril in comparison with calcium-antagonist, felodipine. Int. J. CardioL (1998) 63:175–178.
   PubMed Web of Science ®Google Scholar
• KAHAN T, ELIASSON K: The influence of long-term ACE inhibitor treatment on circulatory responses to stress in human hypertension.. J. Hypertens. (1999) 12:1188–1194.
   Web of Science ®Google Scholar
• SWEDBERG K, AMTORP O, T et al.: Is maximal exercise testing a useful method to evaluate treatment of moderate heart failure? Circulation (1991) 57:226 (Abstr.).
   Google Scholar
• MAASS L: Double-blind comparative trial with ramipril and placebo in patients with heart failure (NYHA class III-IV) stabilized on digitalis and furosemides. Hoechst Aktiengesellschaft, Frankfurt, Germany (1991) [Unpublished report].
   Google Scholar
• GORDON M: Evaluation of the efficacy and safety of ramipril (HOE 498) in patients with congestive heart failure in a placebo controlled trial. Hoechst-Roussel Pharmaceuticals, Somerville, New Jersey (1991) [Unpublished report].
   Google Scholar
• MAASS L: Efficacy and safety of ramipril (HOE 498) in patients with congestive heart failure in a double blind placebo controlled trial. Hoechst Aktiengesellschaft, Frankfurt, Germany (1991) [Unpublished report].
   Google Scholar
• MAASS L: Evaluation of the effect of ramipril (HOE 498) on exercise duration, invasive cardiac hemodynamics profiles, and safety in patients with congestive heart failure. Hoechst Aktiengesellschaft, Frankfurt, Germany (1991) [Unpublished report].
   Google Scholar
• LEMAIRE JC: Multicenter double-blind placebo-controlled study of the efficacy and safety of ramipril administered orally for 24 weeks in the treatment of stable chronic congestive heart failure. Laboratories Hoechst, Paris, France (1992) [Unpublished report].
   Google Scholar
• GARG R, YUSUF S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA (1995) 273:1450–1456.
   PubMed Web of Science ®Google Scholar
• SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. Engl. J. Med. (1991) 325:293–302.
   PubMed Web of Science ®Google Scholar
• THE CONSENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure. Engl. J. Med. (1987) 316:1429–1435.
   PubMed Web of Science ®Google Scholar
• THE AIRE STUDY INVESTIGATORS: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet (1993) 342:821–828.
   PubMed Web of Science ®Google Scholar
• ••An important trial that demonstrated alarge clinical benefit from starting ramipril in the early stages following an acute MI.
   Google Scholar
• HALL AS, MURRAY GD, BALL SG: Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE extension (AIREX) study. Lancet (1997) 349:1493–1497.
   PubMed Web of Science ®Google Scholar
• YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl. J. Med. (2000) 342:145–153.
   PubMed Web of Science ®Google Scholar
• ••A landmark study demonstrating asignificant reduction in important adverse clinical events when using ramipril 10 mg/day for the prevention of vascular diseases in high-risk patients 4.5 years of follow-up.
   Google Scholar
• SVENSSON P, DE FAIRE U, SLEIGHT P, YUSUF S, OSTERGREN J: Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension (2001) 38(6):E28–E32.
   PubMed Web of Science ®Google Scholar
• MARRE M, LIEVRE M, G et al.: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with Type 2 diabetes and raised excretion of urinary albumin: randomized, double blind, placebo trial (the DIABHYCAR study). Br. Med. J. (2004) 328:495–500.
   PubMed Web of Science ®Google Scholar
• EUROPA INVESTIGATORS: Efficacy ofperindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet (2003) 362:782–788.
   PubMed Web of Science ®Google Scholar
• PEACE INVESTIGATORS: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl. J. Med. (2004) 351:2058–2068.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, BRAUNWALD E, MOYE LA et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl. J. Med. (1992) 327:669–677.
   PubMed Web of Science ®Google Scholar
• TEO KK, YUSUF S, SLEIGHT P et al.: Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am. Heart J. (2004) 148:52–61.
   PubMed Web of Science ®Google Scholar
• YUSUF S, GERSTEIN H, HOOGWERF B et al.: Ramipril and the development of diabetes. JAMA (2001) 286:1882–1885.
   PubMed Web of Science ®Google Scholar
• HENRIKSEN EJ, JACOB S: Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism (1995) 44:267–272.
   PubMed Web of Science ®Google Scholar
• VUORINEN-MRKKOLA H, YKI-JARVINEN H: Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependant diabetes mellitus. Metabolism (1995) 44:85–89.
   PubMed Web of Science ®Google Scholar
• HENRIKSEN EJ, JACOB S, TR et al.: ACE inhibition and glucose transport in insulin resistant muscle: roles of bradykinin and nitric oxide.. J. PhysioL (1995) 277:R332–R336.
   Google Scholar
• GERSTEIN HC, YUSUF S, HOLMAN R, BOSCH J, POGUE J, THE DREAM TRIAL INVESTIGATORS: Rationale, design, and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia (2004) 47(9):1519–1527.
   PubMed Web of Science ®Google Scholar
• LONN EM, YUSUF S, DZAVIK V et ell.: Effects of ramipril and vitamin Eon atherosclerosis. The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E. Circulation (2001) 103:919–925.
   Google Scholar
• ••An important substudy of the HOPE trialthat demonstrated a dose-dependent effect of ramipril on the reduction in progression of carotid atherosclerosis.
   Google Scholar
• MACMAHON S, SHARPE N, G et al.: Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J. Am. Coll. Cardiol. (2000) 36:438–443.
   PubMed Web of Science ®Google Scholar
• ESPELAND MA, CRAVEN TE, RILEY WA, CORSON J, ROMONT A, FURBERG CD: Reliability of longitudinal ultrasonagraphic measurements of carotid intimal-medial thickness. Stroke (1996) 27:480–485.
   PubMed Web of Science ®Google Scholar
• THE ATLANTIS STUDY GROUP: Low-dose ramipril reduces microalbuminuria in Type 1 diabetic patients without hypertension. Diabetes Care (2000) 23: 1823-1829.
   Google Scholar
• LI P, CHOW K, WONG T et al.: Effect ofan angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis.. Intern. Med. (2003) 139:105–112.
   Web of Science ®Google Scholar
• THE GISEN GROUP: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet (1997) 349:1857–1863.
   PubMed Web of Science ®Google Scholar
• RUGGENENTI P, PERNA A, GHERARDI G et al.: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet (1999) 354:359–364.
   PubMed Web of Science ®Google Scholar
• WRIGHT JT, BAKRIS G, GREENE T et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA (2002) 288:2421–2431.
   PubMed Web of Science ®Google Scholar
• THE HOPE STUDY INVESTIGATORS: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub-study. Lancet (2000) 355:253–259.
   PubMed Web of Science ®Google Scholar
• THE AMERICAN DIABETES ASSOCIATION: Position statement. of medical care in diabetics. Diabetes Care (2005) 28:S4–S36.
   PubMed Web of Science ®Google Scholar
• THE TASK FORCE ON ACE-INHIBITORS OF THE EUROPEAN SOCIETY OF CARDIOLOGY: Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur. Heart J. (2004) 25:1454–1470.
   PubMed Web of Science ®Google Scholar